Ingemar Turesson
51 – 100 of 123
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study.
(
- Contribution to journal › Letter
- 2011
-
Mark
The association of cancer and venous thrombosis: yes, Trousseau is right ... again!
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
(
- Contribution to journal › Article
-
Mark
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
(
- Contribution to journal › Article
-
Mark
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study
(
- Contribution to journal › Article
- 2010
-
Mark
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(
- Contribution to journal › Scientific review
-
Mark
Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study.
(
- Contribution to journal › Article
-
Mark
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
(
- Contribution to journal › Article
-
Mark
Monoclonal Gammopathy of Undetermined Significance and Risk of Infections A Population Based Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study
(
- Contribution to journal › Article
-
Mark
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
(
- Contribution to journal › Article
-
Mark
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
(
- Contribution to journal › Article
-
Mark
Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? - response
(
- Contribution to journal › Letter
-
Mark
Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom Macroglobulinemia.
(
- Contribution to journal › Article
-
Mark
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.
(
- Contribution to journal › Article
-
Mark
Diagnostik och uppföljning av patienter med små M-komponenter. Med sikte på att undvika transformation till malign sjukdom.
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: A population-based study
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0391-0391(
- Contribution to journal › Published meeting abstract
-
Mark
Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Highly increased familial risks for specific lymphoma subtypes
(
- Contribution to journal › Article
-
Mark
Risk of plasma cell and lymphoproliferative disorders among 14 621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden
(
- Contribution to journal › Article
-
Mark
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
(
- Contribution to journal › Published meeting abstract
-
Mark
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
(
- Contribution to journal › Article
-
Mark
Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance
(
- Contribution to journal › Letter
-
Mark
Improved Survival in Younger Patients with Multiple Myeloma: A Population-Based Study from Malmo, Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
Novel Aspects Pertaining to the Relationship of Waldenstrom's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
(
- Contribution to journal › Scientific review
-
Mark
Autoimmunity and risk for Hodgkin's lymphoma by subtype
(
- Contribution to journal › Letter
-
Mark
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies
(
- Contribution to journal › Scientific review
-
Mark
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study
(
- Contribution to journal › Article
-
Mark
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
(
- Contribution to journal › Article
-
Mark
Genetics- and Immune-Related Factors in the Pathogenesis of Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
(
- Contribution to journal › Scientific review
-
Mark
Incidence of Myeloma Over 56 Years (1950-2006): A Population-Based Study from Malmo, Sweden
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Increased risk of monoclonal gammopathy of undetermined significance (MGUS) and lymphoid tumors among first-degree relatives of MGUS cases
2008) 17th Annual Meeting of the International-Genetic-Epidemiology-Society In Genetic Epidemiology 32(7). p.691-691(
- Contribution to journal › Published meeting abstract
-
Mark
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden
(
- Contribution to journal › Article
-
Mark
Germline Genes Specific to Chronic Lymphocytic Leukemia (CLL) and Genes Common to CLL, Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas Are Important in Susceptibility
(
- Contribution to journal › Published meeting abstract
-
Mark
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
(
- Contribution to journal › Article
-
Mark
Familial Aggregation of Multiple Myeloma and Its Precursor Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study in Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
(
- Contribution to journal › Article
-
Mark
Immune-Related and Inflammatory Conditions Likely Play a Role in the Development of Lymphoplasmacytic Lymphoma/Waidenstrom's Macroglobulinemia.
(
- Contribution to journal › Published meeting abstract
-
Mark
A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0209-0209(
- Contribution to journal › Published meeting abstract
-
Mark
Familial characteristics of Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL): A population-based study in Sweden
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.166-166(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
(
- Contribution to journal › Article
-
Mark
Risk of malignant disease among 1525 adult male US veterans with gaucher disease
(
- Contribution to journal › Article
-
Mark
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003.
(
- Contribution to journal › Article
- 2006
-
Mark
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
(
- Contribution to journal › Article
-
Mark
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
(
- Contribution to journal › Article